Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 10Unknown 3Terminated 3Recruiting 3Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 1Dermatologic 1

Conditions

Colorectal Neoplasms 48Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Non-Small-Cell Lung 15Neoplasms 11Head and Neck Neoplasms 9Neoplasm Metastasis 8Lung Neoplasms 8Pancreatic Neoplasms 7Colonic Neoplasms 7Carcinoma, Squamous Cell 7Solid Tumors 5Rectal Neoplasms 4Ovarian Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Recurrence 2Oropharyngeal Neoplasms 2Melanoma 2Locally Recurrent Rectal Cancer 2Carcinoma, Pancreatic Ductal 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1

Interventions

Fulvestrant 60Capecitabine 47Trastuzumab 46Letrozole 45pembrolizumab 42Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37abemaciclib 36pertuzumab 34Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Surveys and Questionnaires 26Docetaxel 26Tamoxifen 25Anastrozole 25exemestane 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × Cetuximab × Clear all
NCT07318805 2026-05-08

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Pfizer

Phase 1 Recruiting
260 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Recruiting
113 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡